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Which factors impact on quality of life for adults with blepharospasm and 
hemifacial spasm?  
Purpose: Benign essential blepharospasm (BEB) and hemifacial spasm (HFS) are 
debilitating conditions causing spasms to the eyes and/or face and can significantly 
impact on quality of life (QoL). Initial research has highlighted potential factors 
impacting on QoL in BEB, but there remains a wealth of demographic, clinical and 
psychosocial factors that may contribute to QoL but have not received attention. 
Methods: Cross-sectional baseline data were collected before a single-masked 
randomised controlled trial from 130 adults with BEB and HFS recruited from 
botulinum toxin clinics at Moorfields Eye Hospital, London. QoL was measured using 
the 24-item Craniocervical Dystonia Questionnaire (CDQ24), which provides a total 
score and five subscale scores relating to Stigma, Emotional state, Pain, Activities of 
daily living (ADL), and Social/ family life. Treating clinicians provided clinical data. 
Hierarchical multiple regressions were performed on this baseline data to identify 
significant predictors of QoL. 
Results: ADL and Stigma were the areas most impacted upon whilst patients 
experienced better adjustment in relation to Pain, Social/family life and Emotional 
state. CDQ24 Total scores were explained by the model (80% variance) and were 
significantly associated with appearance concerns, emotional representations, perceived 
negative consequences of the condition, mood, and dose of botulinum toxin.  
Conclusions:  Patients with BEB and HFS report a detrimental impact on ADL and 
perceived stigma in relation to their condition.  Predominantly, individual perceptions 
and mood are associated with QoL in this population, rather than demographic and 
clinical factors, signifying areas to target in the design of future healthcare services or 
interventions. 
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Benign essential blepharospasm (BEB) and hemifacial spasm (HFS) are types of movement 
disorders characterised by excessive involuntary contractions in the eyes and face.1;2 BEB 
(persistent closure of both eyes) affects between 16 and 133 per million,3 HFS (spasms 
affecting one side of the face) is estimated to affect up to 100 per million,2 and both 
conditions are more common in adults aged 40 and over.4 Although the pathophysiology of 
these two conditions is different, the illness and treatment experiences of patients share many 
similarities. For instance, both conditions impact on the ability to carry on with normal daily 
activities, such as working or reading.5;2 BEB, and many instances of HFS, are currently 
without a definitive cure. Repeated injections of botulinum toxin are the most effective 
treatment.6 The effects of botulinum toxin injections, however, do not last, resulting in 
periods of relief being followed by a return of symptoms.7. This is reflected in a recent study 
where the chronic, cyclical, and unpredictable nature of the conditions were identified along 
with patients’ understanding of the conditions.8 
A growing body of research has found both conditions to have a detrimental impact on 
psychosocial outcomes, including mood,5;9 and quality of life. 4;10;11 As many as 37% of 
patients with BEB have been found to high levels of self-reported depression,11 and 17% of 
patients with HFS meet the criteria for a clinical diagnosis of major depressive disorder.12 A 
recent systematic review found several determinants of poorer quality of life in BEB 
including patients with lower disease duration, female patients, those with cognitive 
impairments, and psychiatric problems including depression and obsessive-compulsive 
disorder13. Few studies were found to investigate quality of life in HFS13.  
However, while for some patients the impact of the condition is extreme, others are only 
mildly affected. This heterogeneity in adjustment is a common finding across chronic 
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conditions,14 including other chronic eye conditions.15;16 It is useful to determine which 
factors may be contributing to adjustment so that health services can be directed to these 
determinants. Little previous research has investigated the specific factors associated with 
quality of life in BEB and HFS. A number of studies have found evidence for significant 
relationships between quality of life and depression,9; 11; 17 and quality of life and anxiety,18 
(in BEB) and significant relationships between demographic, clinical factors and depressed 
mood,12 and quality of life,17; 19 in HFS. There remain, however, a wealth of individual patient 
perceptions that have not been previously investigated in BEB or HFS and may determine 
psychosocial outcomes. 
There is evidence from a larger body of research in Parkinson’s Disease (PD), also 
characterised by a movement disorder, that individual beliefs and coping styles can determine 
psychosocial outcomes, including mood,20;21 and quality of life.21; 22 It is important to 
understand the range of individual perceptions patients with chronic conditions hold so that 
healthcare and psychological services can be designed to target the most important factors 
contributing to quality of life. With the limited previous research in BEB or HFS, this study 
aimed to investigate the predictive value of demographic, clinical and individual beliefs for 
quality of life in BEB and HFS. 
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Materials and Methods 
Ethics 
Ethical approval was obtained from National Research Ethics Service (NRES) London – 
Queen Square (REC reference 15/LO/0439) in April 2015. Botulinum toxin is part of the 
usual treatment at Moorfields Eye Hospital, London (MEH) and the study adhered to the 
tenets of the Declaration of Helsinki. Written informed consent was obtained from all 
participants.  
Study design 
This article presents a cross sectional study of the baseline data collected for a single-masked 
randomised controlled trial (RCT) to assess the effectiveness of a patient-initiated treatment 
service compared to standard care.23   
Participants 
Participants were recruited between August 2015 and February 2017 from the nurse-led 
botulinum toxin clinics at MEH, London, for the RCT. Patients were aged 18 years or over 
with a diagnosis of BEB or HFS, were stable on botulinum toxin defined as having received 
two previous cycles at stable doses and free from complications, and had mental capacity to 
provide informed consent as judged by the research nurse. Patients attending the nurse-led 
botulinum toxin clinic were identified as eligible by the research nurse and invited to take 
part in the study prior to their next clinic appointment. Patients were approached by their 
treating clinician and those expressing an interest in taking part were recruited by a research 
psychologist. Patients were excluded from the study if they were identified by their treating 
clinician as not having a comprehensive understanding of written or spoken English to 
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complete study measures, or were suffering from psychiatric or co-morbid health conditions 
that rendered them too ill or distressed to take part.  
Measures 
Demographics 
Participants’ age, gender, marital status, ethnicity, employment status, level of education, and 
accommodation and living situation were collected in a questionnaire given to participants on 
the day they were recruited.  
Clinical variables 
Data collected from patients’ medical notes included diagnosis, duration of botulinum toxin 
treatment, number of previous cycles, frequency of previous cycles, last dose of botulinum 
toxin, and any existing comorbidities. Participants also provided the period of experienced 
benefit of botulinum toxin in days, weeks, or months.  
Disease severity. For patients with BEB, disease severity and frequency of symptoms were 
assessed using the Jankovic Rating Scale (JRS),24 a clinician-completed measure consisting 
of two items, each with a score of 0 (no symptoms) to 4 (severe symptoms). Patients with 
HFS were rated on the JRS and received an additional rating scale for severity and frequency 
of cheek involvement based on two items recommended by Wabbels and Roggenkämper.2 
The severity and frequency scores were added to create a sum score, giving participants a 
score between 0 and 8 for the severity and frequency of eye spasms, and participants with 
HFS a score of between 0 and 8 for severity and frequency of check spasms. Higher scores 
indicate more severe and frequent spasms.  
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Disease disability. All participants completed the Blepharospasm Disability Index 
(BSDI)©,25 a patient-reported measure that asks about impairment in six areas: driving, 
reading, watching TV, shopping, walking and doing everyday activities. Each item is rated on 
a scale from 0 (no impairment) to 4 (no longer possible due to illness), with higher scores 
indicating greater disability as a result of the condition. A “not applicable” option is available 
for each item and the total score is a mean item score, calculated by dividing the sum score 
by the number of applicable items. Thus, any participants answering “not applicable” in all 
areas did not receive a score on the BSDI. The measure is also recommended for use in 
hemifacial spasm.2  
Treatment side effects. The occurrence of adverse events from the last treatment including 
ptosis, double or blurred vision, tearing, hematoma and foreign body sensation were also 
recorded by the treating clinician at the point of recruitment.  
Psychosocial variables 
Participants were asked to complete a range of questionnaires included in the pack given to 
them on the day of recruitment.   
Mood. The Hospital Anxiety & Depression scale (HADS) was used to screen for depression 
and anxiety, with higher total subscale scores indicating greater levels of anxious or 
depressed mood.26 Cut-off scores were also applied to identify non-cases (0 to 7), doubtful 
cases (8 to 10), and cases of possible clinical anxiety or depression (scores of 11 and over). 
The HADS has demonstrated excellent internal consistency (Cronbach’s alpha: anxiety 0.68-
0.93; depression 0.67-0.90) and high test-retest reliability (r=0.86-0.89).26  
Appearance concerns. The Derriford Appearance Scale (DAS24) was used to measure the 
impact of appearance-related social anxiety and avoidance, with higher scores indicating 
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greater levels of appearance-related social anxiety and avoidance.27 This measure has 
demonstrated high internal consistency (α = .92) and good test-retest reliability (r=0.82).27 
Illness beliefs. Beliefs about illness were measured using the revised illness perceptions 
questionnaire (IPQ-R).28 The IPQ-R is divided into two sections, with the identity subscale 
presented first as a list of 14 commonly experienced symptoms and respondents judge 
whether each symptom is related to their condition. As recommended by the authors of the 
scale for the purpose of this study, four blepharospasm and hemifacial spasm symptoms were 
added to this scale (i) frequent blinking, (ii) irritation of the eye, (iii) uncontrollable eye 
closure and, (iv) muscle twitching around the face and/or eye; bringing the maximum score 
up to 18.  
The second section of the scale measures all other subscales other than causes. Responses are 
rated on a 5-point Likert scale, from 1 (strongly disagree) to 5 (strongly disagree). To 
increase the validity of the IPQ-R scale, these items were subject to a principle components 
analysis (PCA) to identify the factor structure of the measure specifically in BEB and HFS, 
the methods are described in a recent article8. After one item was removed from the original 
IPQ-R, the measure was found to include ten separate factors: timeline acute, timeline 
chronic, timeline cyclical, illness uncertainty, consequences, emotional representations, 
treatment control, negative personal control, positive personal control, and coherence. The 
new IPQ-R structure was found to possess good internal reliability, with Cronbach’s alphas 
ranging from 0.67 to 0.89, and good construct validity demonstrated by relationships with 
similar variables (Spearman’s rhos ranging from 0.2 to 0.7). High scores on the timeline 
acute, timeline chronic, timeline cyclical, illness uncertainty, consequences, and emotional 
representations subscales represent strongly held beliefs about the incurable, chronic, and 
cyclical nature of the condition, the unpredictability of the condition, and the negative 
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consequences and emotional response associated with the condition, respectively. High 
scores on the negative and positive personal, treatment control and coherence dimensions 
represent positive beliefs about the controllability of the condition and its treatment and a 
personal understanding of the condition.  
Illness cause is assessed in the last 18 items of the IPQ-R, which were also subjected to PCA 
in the present BEB and HFS population, and found to be structured into four subscales: 
psychological attributions, risk factors, lifestyle and chance, which were also found to 
possess good internal reliability, with Cronbach’s alphas ranging from 0.50 to 0.868. 
Treatment beliefs. Beliefs about treatment were measured using the Treatment 
Representations Inventory (TRI).29 This 27 item measure was also subject to PCA in a BEB 
and HFS population and was found to be structured by four factors representing treatment 
value, treatment concerns, decision satisfaction and cure, with higher scores representing 
stronger beliefs about the benefits of treatment in controlling the condition, more anxiety 
about treatment, satisfaction with and suitability of treatment, and the ability of the treatment 
to remove the condition.8 After one item was removed, the subscales demonstrated good 
internal reliability (Cronbach’s alpha: 0.79, 0.84, 0.86 & 0.67 respectively) and has 
demonstrated good construct validity.8; 29  
Quality of life. Quality of life was measured using the Craniocervical dystonia questionnaire 
(CDQ-24),30 which has been used with success in patients with blepharospasm and 
hemifacial spasm.31 The 24 item CDQ assesses quality of life across five domains: stigma, 
emotional well-being, pain, activities of daily living and social/family life. Each item relates 
to issues experienced in the past two weeks, with a scale ranging from 0 (never) to 4 
(always). To obtain comparable scores for the individual subscales, the raw subscores (sum 
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of the individual item score) were linearly transformed to a 0-100 scale, with higher scores 
indicating poorer quality of life.  
Statistical analyses 
All analyses were undertaken using IBM SPSS Statistics Version 22.0. Levels of missing 
data were identified and analysed using Little’s Missing Completely at Random (MCAR) 
test, which if found not to be significant suggests data were missing completely at random. 
Missing data were then dealt with in two stages: first, using mean imputation methods to limit 
the impact of missing data and secondly, multiple imputations were performed where less 
than 50% of data for any variable were missing. If a single case was found to have >50% 
total data missing their data were removed from the analysis. Missing data were not imputed 
for the JRS and BSDI scales, as this would have led to errors in scoring.  
Hierarchical multiple regressions were used to assess which demographic, clinical, and 
psychosocial factors were most strongly associated with quality of life in BEB and HFS. 
Variables entered into each regression model were chosen based on their significant 
associations with each dependent variable (CDQ subscales) in prior univariate regression 
analyses (p<0.05). Subscales within the following categories were entered into the regression 
model in the following order: demographic variables (block 1), clinical variables (block 2), 
appearance concerns (block 3), illness and treatment beliefs (block 4) and mood (block 5). 
Entry methods were used for the hierarchical regressions. Multicollinearity was assessed 
using tolerance and VIF statistics provided in SPSS output and any variables scoring VIF 
statistic over 10 were removed and the regression re-run, to avoid multicollinearity between 
variables.  The same approach was used with the same variables to test their ability to explain 
the variance in each subscale of the CDQ, since each subscale deals with a different aspect of 





During the recruitment period, 247 patients screened by the research nurse were identified as 
eligible and invited to take part in the trial. Five eligible patients did not attend a clinic 
appointment during the recruitment period and 87 declined to participate when approached in 
their clinic visit. A total of 155 patients provided written consent and 130 participants 
returned a baseline questionnaire and were randomised into the trial. After removing one 
participant who missed over 50% of the responses in the questionnaire, all analyses included 
the data for 129 participants. Participant characteristics shown in Table 1. 
[Table 1 near here] 
Missing data 
Little’s Missing Completely at Random (MCAR) test was found not to be significant (χ2 = 
2172.83, df = 2223, p = 0.773), thus data were MCAR. A total of 11.9% of the data were 
missing. Ten imputations were therefore generated, and the analysis was conducted on all 10 
datasets and the results pooled. One participant had over 50% of their total data missing and 
were removed from the analyses.  
 Psychosocial factors 
Participants’ scores on the psychosocial outcome variables are shown in Table 2.  
[Insert Table 2 near here] 
CDQ Total  
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Gender, age, relationship status, housing, experienced benefits of botulinum toxin, diagnosis, 
disability, timing of treatment, last dose, severity of eye spasms, appearance concerns, 
anxiety and depression, illness identity, emotional representations, illness coherence, cyclical 
timeline, consequences, psychological causes, risk factor causes and lifestyle causes, and all 
four treatment beliefs, were found to significantly correlate (p<0.05) with CDQ Total scores 
after univariate regressions.  
The total variance explained by the model as a whole was 79.7% (F26,89 = 13.46, p<0.001). In 
the final model, the variables found to make a unique statistically significant contribution, in 
order of importance (high to low Beta values) were appearance concerns, depression, anxiety, 
emotional representations of the illness, perceived negative consequences associated with the 
condition, and last dose (Table 3). 
[Insert Table 3 near here] 
CDQ Stigma  
Gender, age, relationship status, housing, experienced benefits of botulinum toxin, disability, 
timing of treatment, last dose, appearance concerns, illness identity, emotional 
representations, coherence, consequences, uncertainty, psychological causes, risk factor 
cause, treatment concerns, treatment value, and mood, were all found to significantly 
correlate with CDQ Stigma scores after univariate regressions.  
The total variance in CDQ Stigma scores explained by the model as a whole was 64% (F20,100 
= 8.91, p<0.001). In the final model appearance concerns and depression were found to make 
a unique statistically significant contribution. 
CDQ Emotional state  
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Gender, age, relationship status, housing, living situation, experienced benefits of botulinum 
toxin, disability, timing of treatment, last dose, diagnosis, laterality, number of previous 
cycles, appearance concerns, illness identity, emotional representations, cyclical timeline, 
coherence, consequences, uncertainty, all four causal beliefs, treatment concerns, decision 
satisfaction, treatment value, and mood, were all found to significantly correlate with CDQ 
Emotional State scores after univariate regressions.  
Preliminary analyses indicated that diagnosis, laterality and appearance concerns revealed 
VIF scores above 10, suggesting multicollinearity. After removing laterality from the 
hierarchical regression model, because this was already indicated by whether the condition 
was BEB (both eyes) or HFS (one side of the face), all VIF scores were below 10.  
[Insert Table 4 near here] 
The total variance in CDQ Emotional State scores explained by the model as a whole was 
76% (F27, 93 = 10.69, p<0.001). In the final model, the variables found to make a unique 
statistically significant contribution, in order of importance (high to low Beta values) were 
anxiety, appearance concerns, emotional representations of the illness and perceived negative 
consequences associated with the condition (Table 4). 
CDQ Pain  
Age, housing, experienced benefits of botulinum toxin, disability, timing of treatment, 
severity of eyelid spasms, severity of cheek spasms, appearance concerns, illness identity, 
emotional representations, coherence, consequences, uncertainty, psychological causes, risk 
factor causes, lifestyle causes, treatment concerns, treatment value, and mood, were all found 
to significantly correlate with CDQ Pain scores after univariate regressions.  
14 
 
The total variance in CDQ Pain scores explained by the model as a whole was 39% (F20, 95 = 
3.05, p<0.001). No statistically significant unique predictors for CDQ Pain scores were 
found.  
CDQ ADL 
Gender, experienced benefits of botulinum toxin, disability, timing of treatment, last dose, 
diagnosis, laterality, having a comorbid condition, severity of eyelid spasms, appearance 
concerns, illness identity, emotional representations, coherence, consequences, uncertainty, 
timeline chronic, psychological causes, risk factor causes, treatment decision satisfaction, 
treatment cure, and mood, were all found to significantly correlate with CDQ ADL scores 
after univariate regressions.  
The total variance in CDQ ADL scores explained by the model as a whole was 72.2% (F23, 92 
= 10.40, p<0.001). In the final model, the variables found to make a unique statistically 
significant contribution, in order of importance (high to low Beta values) were disability, 
perceptions of symptoms related to the condition (illness identity) and emotional 
representations of the illness (Table 4). 
CDQ Social/family life  
Gender, relationship status, housing, living situation, disability, timing of treatment, last dose, 
diagnosis, laterality, appearance concerns, illness identity, emotional representations, cyclical 
timeline, coherence, consequences, uncertainty, lifestyle, risk and psychological causes, 
treatment concerns, treatment value, and mood, were all found to significantly correlate with 
CDQ Social/family life scores after univariate regressions.  
The total variance in CDQ Social/family life scores explained by the model as a whole was 
59.4% (F22, 98 = 6.53, p<0.001). In the final model, the variables found to make a unique 
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statistically significant contribution, in order of importance (high to low Beta values) were 





Participants’ essential activities of daily life and experiences with feeling stigmatised were 
the areas most impacted upon. These subscale scores, along with social/family life, and 
overall quality of life, were comparable to other BEB populations.30 However the pain 
subscale scores in this sample was notably lower than other studies suggesting the 
participants in our study were generally not as affected by pain and it is possible that they 
were not representative of the wider BEB population. After initiating treatment with 
botulinum toxin, future regular treatment would normally lead to a reduction in severity over 
time, this having been found in patients with CD,32 which is characterised by involuntary 
movements of the head and neck. Thus maximum severity was unlikely to be observed in this 
study of patients undergoing regular botulinum toxin injections. 
This study also examined the factors associated with quality of life in BEB and HFS where 
there were variations in adjustment. Specifically, better overall quality of life was associated 
with a lower previous toxin dose, less appearance-related distress, less negative emotional 
beliefs about the condition, fewer negative consequences associated with having the 
condition, and better mood. Perceived stigma was associated with greater appearance-related 
distress, and higher levels of depressed mood. Poorer emotional state was associated with 
greater appearance-related distress, more negative emotional beliefs, more negative perceived 
consequences and more anxious mood. As can be expected, greater difficulty in ADL was 
associated with more disease disability, more symptoms, and more negative emotions. Poorer 
social and family life was associated with higher levels of disability, higher previous dose of 
toxin, and more negative emotions. This study indicates that rather than clinical and 
demographic variables, it was the beliefs patients held about their appearance, illness and 
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treatment, which contributed more strongly and consistently to adjustment. Suggesting that 
these factors are suitable targets for improving psychological adjustment in BEB and HFS. 
The finding that neither participants’ demographic factors, nor clinical factors associated with 
the condition, were associated with quality of life in this study contradicts previous 
findings.12 Notably, the diagnosis of either HFS or BEB was not a determinant of difference 
in quality of life measures. This indicates that although the pathophysiology of these 
conditions is different, they share much in their clinical phenotype in terms of facial 
involvement and exposure to very similar treatment modalities, as well as their illness beliefs. 
The finding that mood was associated with all areas of quality of life is in common with 
previous studies in BEB,9;11;17;18 and one study in HFS.17 However this study has expanded 
on previous evidence, also finding that greater appearance-related distress, more negative 
emotional beliefs, negative consequences associated with the condition, greater disability in 
everyday life, and perceived illness identity, are important factors determining poorer quality 
of life in these patient groups.  
This study found that more negative illness beliefs were associated with poorer quality of life 
in BEB and HFS, in particular the negative emotions, perceived consequences of having the 
condition, and the number of symptoms patients associate with their condition. These are 
factors also identified as important in the adjustment of patients with other conditions such as 
coronary artery disease,33 and Parkinson’s disease.22 Moreover, the perceptions found to be 
the strongest predictors of psychological outcomes in a recent meta-analysis across a range of 
long-term health conditions imply that beliefs intervene to improve conditions and are 
therefore important considerations in healthcare practice.34 
The treatment beliefs of patients with BEB and HFS were also examined in this study and 
demonstrated that both groups of patients value their botulinum toxin treatment, are satisfied 
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with the decisions made about using this treatment, believe their injections cure their 
condition, and generally do not have concerns about botulinum toxin. Given that there is 
currently no cure for BEB and HFS and botulinum toxin is the standard treatment, these are 
encouraging findings.  
There are a number of limitations to this study including the cross-sectional design, which 
does not establish causal direction in the associations identified between variables.  In 
addition, as participants were recruited from one centre in the UK, this may limit the 
generalisability of the findings to other locations across the UK and overseas.  
Conclusions 
Patients with BEB and HFS report a detrimental impact deriving from their condition, 
particularly in terms of ADL and perceived stigma.  Predominantly individual perceptions and 
mood were found to be associated with quality of life, rather than demographic and clinical 
factors in this population, which is a finding common across chronic conditions.  Such 
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Table 1. Participants' demographic and clinical characteristics 
Variable Number 
(%) 
Range Mean ± SD 
Age (years)  37 - 88 63.84 ± 10.8 
Gender    
Male 37 (29%)   
Female 92 (71%)   
Ethnicity    
White British/Irish/Other 89 (69%)   
Black African/Caribbean/Asian/Other 40 (31%)   
Diagnosis    
BEB 76 (59%)   
HFS 53 (41%)   
Relationship Status    
Married/Living with partner 80 (62%)   
Single/Other 49 (38%)   
Employment status    
Paid employment 43 (33%)   
Retired/Unemployed/Other 87 (67%)   
Qualifications    
Received GCSEs/A Levels/Degree/Other 102 (79%)   
No qualifications 27 (21%)   
Living situation     
Living alone (with/without children) 37 (29%)   
Living with others 92 (71%)   
Housing situation    
Owner occupied 98 (76%)   
Rented/Other 31 (24%)   
Duration of botulinum toxin (months)  4 - 336 81.4± 71.8 
Number of previous cycles   2-121 21.5± 21.1 
Last dose of botulinum toxin (units)  1.25 - 280 33.9 ± 41.0 
Usual time between treatments 
(months) 
 1 - 9 3.19 ± 1.2 
Side effects from previous treatment    
Ptosis 27 (21%)   
Diplopia 15 (12%)   
Tearing 13 (10%)   
Hematoma 9 (7%)   
Foreign body sensation 11 (8.5%)   
Blurred vision 12 (9%)   
Comorbidities 37 (29%)     
Disease disability (BSDI mean score)  0-3.17 1.1±1.0  
Disease severity (JRS sum score)    
Eyelid spasms  








Table 2. Psychosocial variable scores 
Variable Min Max Max 
Possible 
Mean SD 
CDQ Total score 0 79 96 28.8 20.4 
CDQ Stigma 0 95.8 100 37.8 28.3 
CDQ Emotional wellbeing 0 83.3 100 24.9 21.9 
CDQ Pain 0 41.7 100 8.4 10.9 
CDQ Activities of daily living 0 95.8 100 37.3 25.6 
CDQ Social/family life 0 54.2 100 11.0 14.2 
DAS24 appearance concerns 12 76 96 37.0 13.7 
TRI Subscales      
Decision satisfaction 9 45 45 35.5 5.2 
Treatment concern 6 30 30 16.0 5.1 
Cure 7 34 35 22.0 4.4 
Treatment value 5 25 25 15.9 4.6 
IPQR Subscales      
Identity 0 14 18 5.3  
Chronic timeline 6 20 20 16.8 3.5 
Acute timeline 4 15 15 10.7 2.7 
Emotional representations 5 25 25 14.3 5.1 
Illness coherence 5 25 25 14.0 4.6 
Treatment control 6 15 15 11.4 2.2 
Positive personal control 4 18 20 9.4 3.5 
Negative personal control 2 10 10 5.6 2.1 
Illness uncertainty 3 15 15 9.3 2.5 
Illness consequences 8 29 30 19.3 5.3 
Psychological cause 5 23 25 12.3 4.9 
Risk factor cause 6 22 30 12.1 4.2 
Lifestyle cause 4 16 20 6.8 2.5 
Chance or ageing cause 2 9 10 5.6 2.1 
HADS Depression 0 17.5 21 5.2 4.2 





Table 3. Results of hierarchical multiple regression for CDQ24 Total Score 
Outcome CDQ Total 
Step 
1 2 3 4 5 
Gender 0.22 0.16 0.16 0.07 0.10 
Age -0.14 -0.13 -0.05 0.01 0.04 
Relationship status 0.10 0.11 0.18 0.15 0.05 
Housing -0.09 -0.04 -0.03 0.00 0.04 
Living situation - - - - - 
Experienced benefits - -0.03 0.03 0.01 0.01 
BSDI  - 0.34* 0.28* 0.22 0.14 
Diagnosis - -0.01 0.01 0.05 0.07 
Treatment timing (months) - -0.09 -0.14 -0.12 -0.04 
Last dose (units) - 0.20 0.16 0.14 0.11 
Previous cycles (total) - - - - - 
Laterality - - - - - 
JRS eyelid spasms - 0.06 0.11 0.08 0.08 
JRS cheek spasms - - - - - 
Comorbidities - - - - - 
DAS24  - - 0.37* 0.27* 0.20* 
IPQR Illness identity - - - 0.05 0.11 
IPQR emotional 
representations - - - 0.23 0.16 
IPQR coherence - - - -0.01 -0.05 
IPQR timeline cyclical - - - 0.03 -0.01 
IPQR consequences - - - 0.18 0.15 
IPQR uncertainty - - - 0.07 0.06 
IPQR timeline chronic - - - - - 
IPQR psychological causes 
- - - -0.03 -0.11 
IPQR risk factor causes - - - 0.01 -0.01 
IPQR lifestyle causes - - - 0.06 0.07 
IPQR chance causes - - - - - 
TRI decision satisfaction  - - - -0.03 -0.07 
TRI treatment concern - - - 0.07 0.01 
TRI cure - - - -0.03 0.01 
TRI treatment value - - - -0.04 0.00 
HADS anxiety - - - - 0.18 





Table 4. Results of hierarchical multiple regression for each CDQ24 Subscale 
Outcome CDQ Stigma CDQ Emotional State CDQ Pain CDQ Activities of Daily Living CDQ Social/Family Life 
Step 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 





















0.04 - - - - - - - - - - 
Relationship status 0.12 0.13 0.19 0.17 0.11 0.12 0.11 0.16 0.08 
-





















0.09 - - - - - 
-
0.17 -0.11 -0.09 
-
0.06 -0.04 




0.05 -0.04 -0.09 
-
0.16 - - - - - - - - - - - - - - - 
Experienced benefits - 
-
0.09 -0.02 0.01 -0.02 - 
-




0.02 0.00 0.00 
-
0.01 - -0.07 -0.04 -0.01 -0.01 - - - - - 
BSDI  - 0.17 0.12 0.00 -0.09 - 0.23 0.18 0.09 
-
0.01 - 0.18 0.16 0.04 
-
0.02 - 0.59* 0.57* 0.50* 0.44* - 0.33* 0.29 0.20 0.13 
Diagnosis - - - - - - 
-






0.09 -0.12 -0.13 -0.04 - 
-
0.10 -0.13 -0.13 
-








0.09 - -0.06 -0.06 -0.02 0.02 - -0.13 -0.12 
-
0.11 -0.04 
Last dose (units) - 0.22 0.17 0.14 0.12 - 0.16 0.11 0.07 0.04 - - - - - - 0.14 0.12 0.09 0.08 - 0.22 0.19 0.15 0.14 
Previous cycles (total) - - - - - - 
-
0.12 -0.13 -0.08 
-
0.08 - - - - - - - - - - - - - - - 
Laterality - - - - - - - - - - - - - - - - 0.23 0.22 0.23 0.18 - 0.06 0.04 
-
0.02 -0.08 
JRS eyelid spasms - - - - - - - - - - - 0.15 0.15 0.06 0.05 - 0.11 0.12 0.11 0.10 - - - - - 
JRS cheek spasms - - - - - - - - - - - 0.07 0.07 0.20 0.22 - - - - - - - - - - 
Comorbidities - - - - - - - - - - - - - - - - -0.02 -0.01 0.00 -0.02 - - - - - 
DAS24  - - 0.49* 0.37* 0.32* - - 0.45* 0.30* 0.23 - - 0.12 0.01 
-
0.03 - - 0.20 0.10 0.08 - - 0.34* 0.15 0.11 




representations - - - 0.23 0.20 - - - 0.29 0.22 - - - 0.06 0.01 - - - 0.23 0.20 - - - 0.31 0.27 
IPQR coherence - - - 0.08 0.05 - - - 0.00 
-




0.13 - - - 0.01 0.00 - - - 0.02 0.00 
IPQR timeline cyclical - - - - - - - - 0.03 0.01 - - - - - - - - - - - - - 0.06 0.06 
IPQR consequences - - - -0.03 -0.11 - - - 0.22 0.18 - - - 0.13 0.11 - - - 0.04 0.02 - - - 0.18 0.15 
28 
 
IPQR uncertainty - - - -0.03 -0.04 - - - 0.10 0.07 - - - 0.03 0.02 - - - -0.03 -0.04 - - - 0.04 0.03 
IPQR timeline chronic - - - - - - - - - - - - - - - - - - 0.04 0.04 - - - - - 
IPQR psychological 
causes - - - 0.08 0.07 - - - 0.06 
-




0.16 - - - -0.10 -0.13 - - - 0.01 -0.06 
IPQR risk factor causes - - - -0.01 -0.01 - - - -0.02 
-
0.03 - - - 0.12 0.12 - - - -0.03 -0 - - - 0.05 0.04 
IPQR lifestyle causes - - - - - - - - 0.02 0.04 - - - 0.15 0.14 - - - - - - - - 0.09 0.098 
IPQR chance causes - - - - - - - - 0.01 0.00 - - - - - - - - - - - - - - - 
TRI decision satisfaction  - - - - - - - - -0.01 
-
0.05 - - - - - - - - -0.08 -0.09 - - - - - 
TRI treatment concern - - - 0.15 0.10 - - - 0.08 0.02 - - - 0.09 0.07 - - - - - - - - 0.05 0.05 
TRI cure - - - - - - - - - - - - - - - - - - -0.08 -0.1 - - - - - 
TRI treatment value - - - -0.06 -0.08 - - - -0.11 
-
0.09 - - - 0.01 0.02 - - - 0.03 0.03 - - - 
-
0.07 -0.07 
HADS anxiety - - - - 0.14 - - - - 0.30 - - - - 0.17 - - - - 0.01 - - - - 0.06 
HADS depression - - - - 0.21 - - - - 0.15 - - - - 0.10 - - - - 0.16 - - - - 0.20 
*p<0.001 
